The HBAR Foundation and BCW Ventures Launch a Market Development Fund to Accelerate Growth on the Hedera Network ACN Newswire

The HBAR Foundation and BCW Ventures Launch a Market Development Fund to Accelerate Growth on the Hedera Network

HONG KONG, Jul 12, 2022 - (ACN Newswire via SEAPRWire.com) - The HBAR Foundation and BCW Group today announced a collaboration focused on the rapidly expanding ecosystem at the intersection of distributed ledger technology and digital assets, with an initiative that supports the development and growth of the Hedera network. Kyle Baron, Managing Partner at BCW, and his team will lead and manage an all-encompassing Market Development Fund (MDF) to onboard prominent early-stage projects looking to build on Hedera.BCW is a global fintech-focused strategy consulting and technology firm that works alongside industry-leading partners and clients to scale digital asset infrastructure, remove friction points, and enhance customer experiences to reimagine how the world does commerce. The BCW MDF furthers the HBAR Foundation's support of the Hedera ecosystem by leveraging BCW's expertise in Web3 infrastructure and experience in building scalable digital asset products for Fortune 500 clients. In collaboration with the HBAR Foundation, BCW will continue to identify, incubate, and develop innovative DLT solutions foundational to the growth of next-generation decentralised applications on the Hedera network.The MDF is looking to fund projects focusing on (but not limited to)- Web3 Infrastructure- Decentralised Finance- NFT, Metaverse, and Gaming- InteroperabilityBCW has worked closely with Hedera on a wide range of initiatives since 2018 including hashport, the first interoperability bridge connecting Hedera with the EVM world and TOKO, the enterprise grade digital asset tokenization and issuance platform. BCW has also been a proud sponsor of the Hedera Hackathon since 2020.BCW Ventures enables developers and startups to benefit from BCW's in-house technology and consultancy experts, proprietary multi-chain interoperability and data analytics solutions, and global network of industry founders and partners. BCW grant applicants benefit from the HBAR Foundation's continued technical, marketing, and operational support in addition to other members of the BCW family, like hashport, a multi-chain interoperability solution connecting the Hedera, Polygon, and Ethereum networks that makes making dApp migration and token integration to Hedera easier than ever.To apply for an MDF grant, apply online at https://www.hbarfoundation.org/apply-form and select 'BCW' from the Grant Category dropdown.About BCW GroupBCW Group is a fintech-focused strategy consulting and technology firm with a strong footprint building products & businesses in the digital assets & distributed ledger technologies (DLT) industry. Our mission is to scale digital asset infrastructure, remove the friction points & enhance the customer experience to achieve ubiquity in the utility of digital payments, web 3.0 applications & connectivity of an on-demand digital universe. Our business lines include payments, consulting, technologies, products, research and ventures. We have built products in the areas of blockchain interoperability (hashport), data-analytics (Blockpour), tokenisation (TOKO), staking and IaaS tools (Arkhia).What makes us unique is our ability to not only re-imagine and design the next generation of digital commerce, but to build the applications of the future alongside our world-class partners & clients.Learn more about BCW Ventures at bcw.group or follow us on Twitter and on LinkedIn.- Twitter: https://twitter.com/bcw_llc- LinkedIn: https://www.linkedin.com/company/bcw-group2019About the HBAR FoundationFounded in 2021, the HBAR Foundation fuels the development of the Hedera ecosystem by providing grants and other resources to developers, startups and organizations that seek to launch decentralized applications in DeFi, NFTs, CBDCs, ESGs, gaming and other sectors. In addition to providing funding through a streamlined grant process, the HBAR Foundation acts as an integrated force multiplier through expert support across technical, marketing, business development and other operational functions that are required to scale. For more information, please contact:Rufus DanielThe HBAR Foundationrufus@hbar.fundSOURCE: The HBAR Foundation Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
NEC Corporation strengthens its partnership with Project Management Institute (PMI) in Asia Pacific to drive business agility JCN Newswire

NEC Corporation strengthens its partnership with Project Management Institute (PMI) in Asia Pacific to drive business agility

TOKYO, Jul 12, 2022 - (JCN Newswire via SEAPRWire.com) - NEC Corporation, a leading global IT and network transformation services provider, today announced a strategic partnership with Project Management Institute, the world's leading association for project management, to become a Disciplined Agile (DA) Consulting Partner. Through this partnership, NEC will use DA as a reference model to implement its own business transformation and utilize its experience to develop a consulting business to solve customer problems. As a DA Consulting Partner, NEC will use the DA tool kit to create both a system and a team that can continuously provide customized solutions to help solve their customer's unique agile delivery challenges, enabling true transformation. NEC will have access to PMI's DA subject matter experts to add value to their customer outreach and expand their network and will provide feedback as a Partner Advisor Council member. As a company engaged in DX, NEC utilizes its knowledge to support various customer needs. In order to achieve business agility through this transformation, NEC is required to solve each customer's issues and barriers with an approach that is tailored to the customer. In response to a wide variety of situations, DA is an ideal toolkit that contains many practices to address such situations, enabling users to select the most appropriate practice for each situation to solve problems and make improvements. By leveraging these features and combining them with NEC's own knowledge, DA will be able to support customer transformations with even greater added value.To achieve this, NEC will capitalize on the DA toolkit to solve challenges currently being faced by its own projects and organizations. By providing this to customers as well, NEC will strengthen the customers' agile delivery into something more practical. In addition, NEC will strengthen the internal curriculum for agile human resource development by utilizing the DA certifications (Disciplined Agile Scrum Master - DASM/ Disciplined Agile Senior Scrum Master- DASSM / Disciplined Agile Coach - DAC) provided by PMI, and promote the training of consultants with DA coaching qualifications as human resources who can support transformation not only within the company but also among customers while strengthening the organization. "In an environment of high uncertainty, agility to respond to rapid change is becoming increasingly essential in conducting business," said Shunichi Fukuoka, General Manager of the SI Business Promotion Division, Digital Business Platform Unit, NEC. "We have found DA know-how to be extremely effective in transforming into agile organizations that can respond to diverse situations and challenges. We will contribute to the advancement of DX for our customers and society by collaborating with PMI, a global leader in agile approaches, and providing them with the value of our own achievements and knowledge.""NEC has had a very thorough agile approach and we are pleased to welcome them as the very first Disciplined Agile Consulting Partner for PMI in Asia Pacific," said Ben Breen, Managing Director, Asia Pacific & Global Head of Construction, PMI. "Becoming a true `learning organization' requires a more disciplined approach to agile in which teams are taught to identify and choose a way of working that best reflects the situation they face. Our focus in Japan is to work with project professionals and organizations to assist them to become agile and quickly shift to remote agile strategies as appropriate. I believe that this partnership will accelerate NEC's transformation journey and help them stay agile in these unprecedented times."The Disciplined Agile approach is a comprehensive agile process tailoring tool kit that guides individuals, teams, and organizations to define their optimal "ways of working". For professionals, it helps them learn multiple paths to agility and can improve business performance. For organizations, it empowers them to customize any method - such as Scrum, Kanban, and other mainstream approaches - to drive outcomes that differentiate them from competitors. From agile skills training, and value stream optimization, to guidance for true business agility enterprise-wide, DA is a comprehensive library of agile and lean practices, lifecycles, and strategies, combined with fit-for-context advice for different situations. For more information about the DA toolkit, visit: www.pmi.org/disciplined-agile.About NEC CorporationNEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of "Orchestrating a brighter world." NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at https://www.nec.com.LinkedIn: https://www.linkedin.com/company/nec/YouTube: https://www.youtube.com/user/NECglobalOfficialFacebook: https://www.facebook.com/nec.global/Twitter: https://twitter.com/NEC_corpAbout Project Management Institute (PMI)Project Management Institute (PMI) is the leading professional association for project management, and the authority for a growing global community of millions of project professionals and individuals who use project management skills. Collectively, these professionals and "changemakers" consistently create better outcomes for businesses, community and society worldwide.PMI empowers people to make ideas a reality. Through global advocacy, networking, collaboration, research, and education, PMI prepares organizations and individuals at every stage of their career journey to work smarter so they can drive success in a world of change.Building on a proud legacy dating to 1969, PMI is a not-for-profit, for-purpose organization working in nearly every country around the world to advance careers, strengthen organizational success, and enable project professionals and changemakers with new skills and ways of working to maximize their impact. PMI offerings include globally recognized standards, certifications, online courses, thought leadership, tools, digital publications, and communities.Visit us at www.PMI.org, www.projectmanagement.com, https://www.linkedin.com/company/projectmanagementinstitute,https://www.facebook.com/PMInstitute, and on Twitter @PMInstitute. Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)
More
Double Monza podium for TOYOTA GAZOO Racing JCN Newswire

Double Monza podium for TOYOTA GAZOO Racing

TOKYO, Jul 11, 2022 - (JCN Newswire via SEAPRWire.com) - TOYOTA GAZOO Racing earned a dramatic double podium finish in the 6 Hours of Monza after an exciting but ultimately frustrating fourth round of the 2022 FIA World Endurance Championship (WEC).Both GR010 HYBRIDs were strong contenders for victory in an incident-packed race at the Temple of Speed, but suffered misfortune in the heat of Hypercar competition.Fresh from their Le Mans 24 Hours win, Sebastien Buemi, Brendon Hartley and Ryo Hirakawa overcame an early technical issue on their #8 GR010 HYBRID to finish second, only 2.762secs behind the winning #36 Alpine.Last year's Monza winners, Mike Conway, Kamui Kobayashi and Jose Maria Lopez in the #7 GR010 HYBRID, were leading when they lost time following contact with the Alpine. The reigning World Champions finished third, two laps behind.A spectacular race among four Hypercar manufacturers leaves both World Championships wide open going into the final two races. TOYOTA GAZOO Racing leads the manufacturers' standings by 15 points from Alpine, while the #8 crew are second in the drivers' rankings, 10 points behind their Alpine counterparts.The two GR010 HYBRIDs were part of a close race from the very beginning. After a clean start, Sebastien drove brilliantly to hold second place under pressure from Alpine, while Jose was close behind in fourth.Two full course yellows in the opening 30 minutes saw all Hypercars make fuel stops. Smart strategy elevated Sebastien into second and Jose into third, although they were unable to challenge the race-leading Glickenhaus.Late in the first hour, Sebastien's race was interrupted by an electrical issue. He managed the issue well but could not avoid dropping two positions on track, including losing second to Jose. A system reset at his next scheduled pit stop cost 30 seconds and put him fifth but the car was back on the pace and Sebastien overtook Peugeot #94 for fourth.A full course yellow around one-third distance triggered the next pit stops. Mike took over the #7 car and diced for second place with the Alpine, while Brendon resumed in the #8.The complexion of the race changed after two-and-a-half hours when an accident from a GT competitor necessitated a safety car and closed up the field. All Hypercars pitted and Mike overhauled the Glickenhaus for the lead, thanks to a shorter pit stop.When the race resumed at half distance, Brendon moved into second when Glickenhaus served a drive-through penalty for a speeding infringement. He held position until the next pit stops, despite a sustained challenge from the Alpine.The top three Hypercars were separated by only a few seconds going into the final two hours and the positions alternated at each pit stop as a result of TOYOTA GAZOO Racing and Alpine changing tyres at different intervals.Towards the end of the fifth hour, with Kamui leading a GR010 HYBRID one-two, Ryo heroically held off the Alpine, which was on fresher tyres, for several laps before dropping to third on lap 153. A lap later, Kamui was defending the lead on the start-finish straight when the #7 and the Alpine made contact.The #7 sustained a right rear puncture and damage to its bodywork, and Kamui returned slowly to the pits for repairs. Thanks to a full course yellow, he lost only one lap and returned in third. When racing resumed with an hour remaining, Ryo was second and putting pressure on the race leader.Ryo showed impressive speed, as well as skill through the traffic, to keep the pressure on and he closed to within three seconds at the chequered flag. Kamui, who served a 90-second penalty as a result of the incident with the Alpine, took the flag in the #7 in third, two laps behind.TOYOTA GAZOO Racing therefore travels to the 6 Hours of Fuji with a point to prove, intent on returning to winning ways in its home race. The team has won seven of its eight races at Fuji Speedway and expects to challenge for another victory on 11 September in the penultimate round of the 2022 season.For more information, visit https://toyotagazooracing.com/wec/release/2022/rd04-race/. Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)
More
Quantum Generation Announces Partnership with Plato Technologies and the Quantum Space Revolution ACN Newswire

Quantum Generation Announces Partnership with Plato Technologies and the Quantum Space Revolution

Raleigh, NC, July 7, 2022 - (ACN Newswire via SEAPRWire.com) - Quantum Generation® is pleased to announce an orbital and terrestrial technology partnership with Plato Technologies. The partnership allows the development of the quantum space-based infrastructure. We are building the quantum incentivized network and integrating the technologies in the space-based QPhone.Quantum computers and communications promise to operate millions of times faster than traditional technologies. Quantum Generation® is deploying the QG® waves technologies with quantum frequency stronger than 5G or 6G. Integrating Plato Blockchain with Quantum Generation® key distribution will ensure it is secure and anonymous. Utilizing the quantum generation repeaters and QSAT™ satellites, Plato Blockchain provides the fastest and most secure platform in the world.Quantum repeaters are a vital component of quantum mesh network. The Plato and QUBIT space "nodes" can receive and transmit quantum data to and from the ground via free-space optical communications.Plato and Quantum Generation® building the viability of technologies with self-healing P2P orbiting nodes to connect quantum transmitters and receivers over great distances securely. These nodes must produce and detect pairs of entangled photons with the Quantum Generation® Repeaters. They are eventually transmitting such photons for quantum cloud computing, the internet, communications, and fintech –exchanging quantum data regardless of where the nodes are located.Quantum Generation's® exclusive QG® 369 community is growing worldwide and has seen an increase in its memberships platform and look forward to building on with the Plato community and creating new ideas, investments, and technologies.About Quantum Generation: Space Based Quantum EcosystemAbout Quantum Generation: Space-Based Quantum Ecosystem™ QUBIT Blockchain® Satellites and Quantum Generation® Quantum Mesh Network™. Creating the QG® (Quantum Generation®) Social Community. For more information, visit https://quantumgeneration.io.About PlatoPlato is an open intelligence repository and browser that unlocks the power of Vertical Search in a highly scalable and value driven way. The Platform is designed to provide an ultra-secure environment to consume specific real-time data intelligence across 27 Languages and through an intuitive and immersive user experience. For more information, visit https://Platodata.ai.Source: Plato Data Intelligence Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
ReviewRumble 2022 Award Winners – Purapeel ACN Newswire

ReviewRumble 2022 Award Winners – Purapeel

SYDNEY, Jul 6, 2022 - (ACN Newswire via SEAPRWire.com) - PuraPeel Aesthetics wins the 2022 Award for best aesthetics business.The ReviewRumble annual awards recognize products and services that have been rated highly by the ReviewRumble community.These awards are completely independent. Any listing can qualify to win an award as long as it meets the judging criteria below.How are award winners determined?To be eligible for an award, a product or a service must meet these requirements:- Listed on the ReviewRumble website for consideration for an award- In business for at least a year- Minimum average rating of 4.1 stars online- Ten or more approved reviews written and approved over the last five yearsFrom this nomination list, the ReviewRumble team performs qualitative analyses and metric comparisons to calculate a 'sentiment score' to determine a category winner. In particular, the proportion of five-star to one-star reviews is taken into account, with more weight being given to reviews written in the last 12-months. In cases where the sentiment score is very close, we may award multiple listings within the category.2022 Award WinnerPuraPeel Aesthetics is a clinic that offers skin treatment. Tania Quan is the founder of PuraPeel. Quan and her team discovered the PuraPeel treatment which is now one of the most popular treatments in Australia.PuraPeel treatments provide deeper cleansing and extractions with suction that would otherwise have to be done manually.About PuraPeel AestheticsA state-of-the-art facial treatment system that offers a multi-functional Hydra-Dermabrasion machine and advanced technology all in one.PuraPeel Aesthetics components are made available to the highest specifications while partnering with industry leaders to create advanced medical-grade products that work in synergy with our PuraPeel devices.Contact details:Tania Quan0449 788 289https://www.purapeelaesthetics.com/SOURCE: PuraPeel Aesthetics Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
U.S. FDA Accepts and Grants Priority Review for Eisai’s Biologics License Application of Lecanemab JCN Newswire

U.S. FDA Accepts and Grants Priority Review for Eisai’s Biologics License Application of Lecanemab

TOKYO, Jul 6, 2022 - (JCN Newswire via SEAPRWire.com) - Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) under the accelerated approval pathway for lecanemab (development code: BAN2401), an investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD (collectively known as early AD) with confirmed presence of amyloid pathology in the brain. Eisai's application, which was completed in early May 2022, has been granted Priority Review, with a Prescription Drug User Fee Act (PDUFA) action date of January 6, 2023."Alzheimer's disease is a serious disease that causes significant disability and burden to the people living with Alzheimer's disease and their families. Treatment options for Alzheimer's disease are limited and creation of new treatment options is strongly encouraged. Eisai employees have spent time with people living with Alzheimer's disease to truly understand their feelings and challenges and have been working to create new treatments for many years," said Haruo Naito, Chief Executive Officer at Eisai. "The acceptance of lecanemab's BLA with priority review is an important milestone in serving people living with Alzheimer's disease who have been waiting for new treatment options to address an underlying pathology of Alzheimer's disease. We will continue to actively cooperate with the FDA's review in an effort to bring this new treatment option to people living with Alzheimer's disease and their families as soon as possible.""We believe in a future where people living with Alzheimer's disease will have different treatment options to address this complex disease, and today's BLA acceptance with priority review by FDA is an important step towards this vision," said Michel Vounatsos, Chief Executive Officer at Biogen. "Together with Eisai, we are committed to continuing our work to address the tremendous unmet need for these patients and their families."The Clarity AD Phase 3 clinical study for lecanemab in early AD is ongoing and Eisai completed enrollment in March 2021 with 1,795 patients. The readout of the primary endpoint data of Clarity AD will occur in the Fall of 2022. The FDA has agreed that the results of Clarity AD, when completed, can serve as the confirmatory study to verify the clinical benefit of lecanemab. Eisai utilized the FDA's Accelerated Approval Pathway in an effort to streamline the submission process for the potential traditional approval of lecanemab in order to expedite patients' access to lecanemab. Dependent upon the results of the Clarity AD clinical trial, Eisai will submit for traditional approval of lecanemab to the FDA during Eisai's fiscal year 2022, which ends on March 31, 2023.In Japan, in March 2022, Eisai initiated the submission of application data to the Pharmaceuticals and Medical Devices Agency (PMDA) under the prior assessment consultation system with the aim of obtaining early approval for lecanemab. Eisai aims to file for the manufacturing and marketing approval based on the results of Clarity AD during Eisai's fiscal year 2022. Also, in Europe, based on the results of the Clarity AD study, Eisai plans to submit a new drug application in fiscal year 2022.Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.For more information, visit www.eisai.com/news/2022/pdf/enews202254pdf.pdf. Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)
More
QualityKiosk and BrowserStack Announce Partnership Extension to the US, EMEA and APAC ACN Newswire

QualityKiosk and BrowserStack Announce Partnership Extension to the US, EMEA and APAC

MUMBAI, INDIA, Jul 5, 2022 - (ACN Newswire via SEAPRWire.com) - QualityKiosk Technologies, one of the largest independent global quality assurance service providers, announced that it is extending its partnership with BrowserStack, a leading cloud-based testing platform enabling on-demand, cross-browser and cross-device testing, into the international regions of US, EMEA and APAC. QualityKiosk's strong domain experience in quality assurance and performance engineering combined with the BrowserStack platform will enable enterprises in the region to create and deploy quality and bug-free software at pace and scale.Speaking on occasion, Mr Maneesh Jhawar, CEO & Founder, QualityKiosk Technologies, said, "QualityKiosk's QA solutions and services, coupled with the BrowserStack platform, provides enterprises with an end-to-end DevOps synergy to optimize the development, management, and up-gradation of all aspects of their business application. The partnership extension is a natural progression to helping businesses scale their digital transformation and evolution in the regions. We are excited for this new growth phase and look forward to working with BrowserStack to bring more innovative solutions and strategies for the region's expanding digital ecosystem.""We're excited to take our partnership with QualityKiosk to the next step. BrowserStack and QualityKiosk share a common objective of empowering organizations to be more agile in their DevOps practices and support them throughout the SDLC process," said Sunil Jose, EVP, Global Sales, BrowserStack. "Expanding to APAC and the US allows us to help businesses scale their testing and quality assurance needs with our partnership's dual expertise."The QualityKiosk-BrowserStack synergy has already enabled numerous businesses in the Indian subcontinent to automate, streamline, and optimize quality assurance to sustainably accelerate digital innovation, enhance end-user experiences, reduce go-to-market times and integrate agility into their development cycles. Their illustrious clientele includes some of the biggest enterprises from the banking, financial services, manufacturing, automotive, telecom, entertainment, and pharmaceutical industries.About QualityKioskQualityKiosk Technologies is a global Quality Assurance (QA) solutions provider and caters to some of the biggest names in the banking and financial services, telecom, and automobile industries across the globe. Founded in 2000 by IIT-Kanpur graduates, the company is a pioneer in digital performance engineering and offers a diverse set of quality assurance solutions including QA automation, performance assurance, Robotic Process Automation (RPA), synthetic monitoring, site reliability engineering (SRE), digital testing as a service (DTaaS), and data analytics solutions for an array of industries and verticals. In the past, the company has been featured in various industry-leading reports by prestigious global advisory firms Forrester and Everest Group. Visit https://www.qualitykiosk.com/ to know more about innovative quality assurance and performance engineering solutions.About BrowserStackBrowserStack is the world's leading software testing platform powering over two million tests every day across 15 global data centers. BrowserStack helps Tesco, Shell, NVIDIA, Discovery, Wells Fargo, and over 50,000 customers deliver quality software at speed by moving testing to their Cloud. BrowserStack's platform provides instant access to 3,000+ real mobile devices and browsers on a highly reliable cloud infrastructure that effortlessly scales as testing needs grow. With BrowserStack, Dev and QA teams can move fast while delivering an amazing experience for every customer. Founded in 2011, BrowserStack is a privately held company backed by Accel, Bond, and Insight Partners. For more information, visit https://www.browserstack.com.For more information, please contact:Naeem Shaikh+91 9819543757naeem.shaikh@qualitykiosk.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More

EQS-News: CICC Initiates Sirnaomics (2257.HK) at Outperform Rating with Target Price of HKD106.00

EQS-News / 04/07/2022 / 17:56 UTC+8 CICC Initiates Sirnaomics (2257.HK) at Outperform Rating with Target Price of HKD106.00 China International Capital Corporation (CICC) initiates coverage of Sirnaomics at “Outperform” rating, with a target price of HKD106.00. CICC said, Sirnaomics is an RNA therapeutics pioneer in China. RNA therapeutics is a rapidly growing field with potential in various indications. Sirnaomics has disclosed over 15 candidates, including two in the clinical stage. STP705 is a siRNA candidate acting as dual TGF-β1/COX-2 inhibitor for local administration. CICC expect STP705 to be marketed in the US in 2024 and in China in 2025, and generate global risk adjusted peak sales of US$617mn in 2031. STP707 is a siRNA candidate also targeting TGF-β1/COX-2 but with potential for systemic administration. CICC expect STP707 to be marketed in 2026 and we estimate it will generate global risk adjusted sales of US$376mn by 2037. Sirnaomics owns proprietary RNA delivery platforms to solve principal challenges to RNAi therapeutics. Sirnaomics has proprietary polypeptide nanoparticle (PNP) and novel N-acetyl galactosamine (GalNAc) delivery platforms. PNP delivery platform allows delivery of both siRNA and mRNA to target cells via local or intravenous administration in low toxicity. It is easy to manufacture and can reach more additional targeted organs other than the liver. CICC believe PNP could have wider use if STP707 has positive read-out in its proof of concept (PoC) trials. Therefore CICC initiates coverage of Sirnaomics at “Outperform” rating. File: CICC Initiates Sirnaomics (2257.HK) at Outperform Rating with Target Price of HKD106.00 04/07/2022 Dissemination of a Financial Press Release, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. Media archive at www.todayir.com
More
Register for the Course! 5th Edition of Global CX Summit India Physical Conference on July 7 ACN Newswire

Register for the Course! 5th Edition of Global CX Summit India Physical Conference on July 7

INDIA, Jul 4, 2022 - (ACN Newswire via SEAPRWire.com) - After successful 4 editions of Global CX Summit, Exito (www.exito-e.com/) is all set to host another milestone event - which serves as an ideal platform to enhance the experience to latest insights in "Orchestrating a Holistic CX Strategy". The agenda is carefully curated to address challenges faced along multiple touch points, helping you overcome various silos. Through engaging panel discussions, insightful keynotes and immersive networking sessions, the event is sure to incite both thought and action at your organization. 5th Edition GCX India (https://globalcxsummit.com) is meticulously curated in alignment with the above initiatives. The summit provides an ideal opportunity to connect, learn and network with like-minded peers from various enterprises of India.The event will be elated with insightful sessions by the qualified speakers hosting a vast experience in the customer experience domain. An exclusive one-day closed door conference hosting 120+ CX Heads, CMOs, CDOs, Contact Center heads, etc to discuss the best practices on customer experience from various enterprises of India.Speakers like Zeenat Mongal, VP & Head Of CX, ICICI Lombard, Hari Shankar Mishra, Sr Vice President - Customer Experience, Future Generali India Insurance Co. Ltd, Dharmarajan K, Chief Business Officer - Beauty, Tata CliQ, Ankit Goenka, Senior VP, Bajaj Allianz General Insurance Co. Ltd, Mayank Jain, Group Digital Customer Initiatives, Aditya Birla Capital, among many others will be sharing their experiences and expertise at the Summit.Event registration has commenced for Delegates (bit.ly/3acaN8x) and Sponsors.- The delegates will be exposed to in-depth, trend-forward sessions & workshops - practical takeaways and ideas to keep you ahead in the digital economy.- The sponsors will be able to create an overwhelming branding in the event along with meeting their prospects and displaying the products.- Hundreds of seasoned marketers, strategists, designers, and more to network and connect with. Meet your customers, vendors, expert resources, friends and colleagues on the 7th of July 2022.Register Today to engage at this grand event as the slots are filling up fast.To know more about the event, https://globalcxsummit.com/. About ExitoWe are a global B2B business events company focused on crafting bespoke solutions and contexts by designing platforms that create new business opportunities for our clients across concepts and industries. We cherish the trust over the last 12 years garnered from our partnering organizations globally, and with a growing team of young, vibrant, and creative individuals, Exito aims at success and perfection. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
IBI Group Announces FY2022 Annual Results, Steadfast Resilience Albeit Market Challenges ACN Newswire

IBI Group Announces FY2022 Annual Results, Steadfast Resilience Albeit Market Challenges

HONG KONG, Jun 30, 2022 - (ACN Newswire via SEAPRWire.com) - IBI Group Holdings Limited ("IBI" or the "Company", together with its subsidiaries as the "Group"; Stock Code: 1547), a publicly listed company that holds investments in companies focusing on the Built Environment, today announced its business results for the financial year ended 31 March 2022 ("FY2022").During the year under review, the Group recorded an income of approximately HK$405.9 million (FY2021: HK$556.7 million). Gross profit was approximately HK$68.0 million (FY2021: HK$79.4 million) and profit attributable to the owners of the Company was approximately HK$27.0 million compared with approximately HK$54.4 million from the previous financial year (which included a one-off gain of approximately HK$43.6 million generated from its strategic investments segment). Basic and diluted earnings per share was HK3.4 cents (FY2021: HK6.8 cents).The Group maintained a strong financial position with cash and cash equivalents of approximately HK$141.6 million (FY2021: HK$87.1 million) and no bank borrowings as at 31 March 2022. The Board has recommended payment of a final dividend of HK1.0 cent per share for the year ended 31 March 2022 (FY2021: HK4.0 cents).Business Review1. ContractingIBI provides world-class interior fitting out and building refurbishment services in Hong Kong and Macau, undertaking two main types of projects namely fitting-out projects and alteration and addition projects. Owing to its established reputation and proven track record, the Hong Kong component of the Company remained busy during FY2022 despite the continuing shadow cast by the Covid-19 pandemic, completing 11 fitting-out projects and being awarded 14 more. During the year under review, revenue from the segment totaled approximately HK$403.9 million (FY2021: HK$511.0 million) with segmental gross profit increasing by an exceptional 91.0% amounting to approximately HK$67.4 million. 2. Building SolutionsIn April 2020, IBI set up its subsidiary, Building Solutions Limited ("BSL"), a provider of products and services that enhance the performance and well-being of the built environment in order to provide modern, healthy and high-performing spaces for its occupants. During the year under review, BSL has been working diligently to develop the business and secure orders. The second year of its operations has shown significant penetration into the market, leading to improved sales figures. BSL has additionally secured distribution rights to a cutting-edge lighting product that has been very well received and will be reflected in the sales figures for the coming financial year. BSL registered a segment loss of approximately HK$2.7 million in FY2022.3. Strategic InvestmentsThe financial year was spent in part, divesting the Group of its earlier stock investments which had generated phenomenal returns in the previous reporting period. In addition, IBI's efforts were targeted toward property-related investment deals and these efforts have generated considerable early success. During the latter part of FY2022, the Group secured development land in Hokkaido, Japan located in close proximity to a future station of the planned Shinkansen high-speed rail line, and is now working with a local development specialist to establish the most efficient use of the land and the timing of the development. Moving forward, the Group will continue to look at potential investment opportunities. Subsequent to the financial reporting period, the Group recently acquired Adelaide Chambers, a building located in the heart of Dublin, Ireland. The investment is a period building with approximately 20,000 square feet of commercial office space and is a value-add proposition with improvements to be made, in both building upgrades and lease improvements, in order to increase the overall asset value and to secure additional profits for the Group.ProspectsHong Kong has now lifted many of the restrictions put in place during the pandemic and life is very quickly returning to normal. The Group is optimistic that Hong Kong will start to regain its full international status once the city's strict quarantine restrictions are further reduced, returning to more normal business activity levels along with stabilization of the market environment. Moving forward, the Group is confident that the capital allocated for its investment will be fully vested within the coming financial year.Mr. Neil Howard, Chairman and CEO of IBI, said, "Amid unprecedented challenges created by COVID-19 pandemic, we have remained steadfast and resilient in driving our growth and investment strategies. IBI is excited for the year ahead and believes that the business environment will move from strength to strength as we slowly transition into the pre-pandemic period. As a result of our strategic business decisions, IBI continued to deliver stable performance and we are extremely proud to be able to retain our full workforce during these challenging times. We are thrilled to see growth in our subsidiaries, especially BSL, and look forward to reporting significantly improved financials as it moves out of its infancy and into its development phase. Our FY2022 results are a testament to our ability to provide integrated, innovative solutions and we look forward to bringing stronger results and add long-term value to shareholders."About IBI Group Holdings Limited (stock code: 1547)IBI Group Holdings Limited is a publicly listed holding company on the Hong Kong Stock Exchange, focused on investments in the Built Environment. The Group's investments whilst principally centering around the role of contracting, including businesses providing an innovative, high-quality product and supply solutions across a diverse range of the built environment. Our mission is to deliver premium products, services and customer experiences with a strong influence on innovation, sustainability and wellness. For more information, please refer to IBI's website: https://ibighl.com/. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Regina Miracle Fiscal 2022 Results Hit Record High, Revenue Increased by 39.7% to HK$8.35 Billion, Adjusted Net Profit More than Doubled to HK$582 Million ACN Newswire

Regina Miracle Fiscal 2022 Results Hit Record High, Revenue Increased by 39.7% to HK$8.35 Billion, Adjusted Net Profit More than Doubled to HK$582 Million

HONG KONG, Jun 29, 2022 - (ACN Newswire via SEAPRWire.com) - Regina Miracle International (Holdings) Limited ("Regina Miracle" or the "Company", together with its subsidiaries, collectively the "Group") (HKEX: 2199), a leading global intimate wear company boasting an Innovative Design Manufacturer ("IDM") business model, has announced its annual results for the year ended 31 March 2022 (the "year" or "Fiscal 2022").During the year, despite the various challenges in the macro environment, the Group's revenue hit a historical high of approximately HK$8,346.7 million (Fiscal 2021: HK$5,974.3 million), representing a year-on-year increase of 39.7%, which was in line with the expected progress of the Group's five-year plan. Gross profit grew correspondingly by 65.2% to approximately HK$2,045.4 million, with the gross profit margin up by 3.8 percentage points to 24.5% (Fiscal 2021: HK$1,238.0 million and 20.7%, respectively). As the satisfactory revenue growth and effective cost control measures resulted in enhanced operating leverage, earnings before interest, taxes, depreciation and amortization (EBITDA) increased by 62.5% to approximately HK$1,333.8 million, with the EBITDA margin up by 2.3 percentage points to 16.0% (Fiscal 2021: HK$820.6 million and 13.7%, respectively). The Group recorded a net profit of approximately HK$520.7 million for the year, representing a year-on-year increase of 314.8%, with the net profit margin up by 4.1 percentage points to 6.2% (Fiscal 2021: HK$125.5 million and 2.1%, respectively). Basic earnings per share attributable to owners of the Company were HK42.5 cents (Fiscal 2021: basic earnings per share of HK10.3 cents). Excluding the one-off expense item arising from the surrender of parts of the leased factory in Shenzhen during the year, the adjusted EBITDA was approximately HK$1,394.9 million with an adjusted EBITDA margin of 16.7%, while adjusted net profit was approximately HK$581.8 million with an adjusted net profit margin of 7.0%.The Group is in a sound financial position, with cash and cash equivalents increasing to approximately HK$995.0 million during the year (Fiscal 2021: HK$828.0 million). It has undrawn banking facilities of approximately HK$2,371.0 million in total as at 31 March 2022 (31 March 2021: HK$2,391.0 million). In order to share the fruitful results with shareholders, the Board has resolved to declare a final dividend of HK7.2 cents per share for Fiscal 2022 (Fiscal 2021: HK3.3 cents per share), together with the interim dividend of HK6.8 cents per share, making a total dividend of HK14.0 cents, in line with the Group's dividend policy of distributing no less than 30% of its net profit for the financial year.Mr. YY Hung, Chairman, Chief Executive Officer & Executive Director of Regina Miracle, said, "While the Pandemic has further reshaped the global landscape, industry leaders with strong R&D capabilities, large scale, rapid response and multi-regional production capacity layout are strongly favored by the market, reflecting the fact that the strong get stronger. Furthermore, highly viscous brand partners have fully resumed their businesses operations and there is a greater demand for innovative designs appealing to consumers. The emphasis on continuous innovation, delivering speed and consistent quality of supply chain partners is gaining importance, while the approach to innovation-led services is increasingly valued and favored. Through six years of investment in innovation, automation and digital production, as well as the refinement of its production capacity layout, Regina Miracle has established a solid business foundation and formulated a five-year plan for Fiscal 2022 to 2026 tapping multiple favorable factors to fully capitalize on this golden period of growth. In the face of the diversified product needs driven by users' changing lifestyles, and increasingly flexible supply chains and production cycles, the Group will continue to focus on various business segments to provide appropriate integrated solutions for different needs."Business ReviewOrders from European and American brand partners have fully recovered, thus the intimate wear segment has soared by more than 60%, exceeding the pre-epidemic levelDuring the year, this segment contributed approximately HK$4,716.0 million in revenue (Fiscal 2021: HK$2,886.0 million), a year-on-year surge of 63.4%, accounting for 56.5% of the Group's total revenue, and remaining the main source of revenue for the Group. The segment's gross profit grew by 94.1% to approximately HK$1,189.2 million, with the gross profit margin up by 4.0 percentage points to 25.2% (Fiscal 2021: HK$612.6 million and 21.2%, respectively). As a result of the better-than-anticipated recovery of the European and U.S. markets during the year, and the strong rebound in orders from the Group's largest U.S. partner, the segment revenue hit a record high, with orders for traditional intimate wear rebounding and surpassing pre-epidemic levels. Drawing on its industry-leading R&D capabilities and innovative craftsmanship, Regina Miracle was able to fully capture the opportunities arising from the easing of the Pandemic, and to work with its major brand partners to seize market opportunities whenever and wherever they arose through flexible production capabilities. In addition, the Group added a number of new emerging PRC e-commerce brands during the year, making its brand partner portfolio more diversified and paving the way for future business growth.The sports product segment remained resilient, with revenue rising by more than 30% year-on-year, with continued product mix enrichmentThis business segment contributed approximately HK$2,190.7 million in revenue during the year (Fiscal 2021: HK$1,596.4 million), a 37.2% year-on-year increase, accounting for 26.3% of total revenue. Segmental gross profit was approximately HK$513.9 million and the gross profit margin was 23.5% (Fiscal 2021: HK$298.9 million and 18.7%, respectively). As the Pandemic eased and the sports craze continued, related products maintained a strong performance, with the order momentum for sports bras from international brand partners being especially strong and thus serving as the main growth driver of this business segment. During the year, the sports leggings product category also showed great momentum through an enriched brand partner portfolio and represented a promising incremental growth driver for the sports products segment. Riding on the emergence of the "Metaverse" concept, the consumer electronics components segment has grown by more than 60% year-on-year, highlighting broad development spaceRevenue from this business segment amounted to approximately HK$496.2 million (Fiscal 2021: HK$291.4 million), representing a significant year-on-year increase of 70.3% and accounting for 5.9% of the Group's total revenue. The segment's gross profit increased by 79.5% to approximately HK$125.0 million, with the gross profit margin up by 1.3 percentage points to 25.2% (Fiscal 2021: HK$69.7 million and 23.9%, respectively). The demand for consumer home electronics continued to rise amid the Pandemic during the year, and with the rapid emergence of the "Metaverse" concept, demand for 5G and related products grew considerably and continuously during the year. As consumer electronics are high value-added products and there is ample room for market development, the segment will continue to generate a new growth impetus for the Group in the future.The revenue from production in Vietnam rose to 80%, with multi-regional production capacity layout fully meeting the enthusiastic demand from domestic and overseas brand partnersAs an important production base of Regina Miracle, Vietnam provides a solid foundation to support the continuous growth of the Group's export business. As of 31 March 2022, the revenue from production in Vietnam rose to 80% of the total revenue of the Group. During the year, the Group completed its factory layout at the Vietnam Singapore Industrial Park in Hai Phong City ("VSIP Hai Phong"), Vietnam. It is worth mentioning that the Group's recruitment and staff stability in the region have been satisfactory, enabling the Group to benefit to the maximum extent from the increasing proportion of mature employees, long service of employees and the master-apprentice model, ensuring that the production capacity and efficiency of each factory will increase year on year. To meet the robust demand of domestic and overseas brand partners as the market resumes, it will be the Group's top priority to continuously enhance the efficiency and effectiveness of its five factories. Through the addition of new production lines and further implementation of automation and digitalization, the overall production capacity in Vietnam will be further increased. After four to six years of integration, the current operation and labor efficiency, as well as the single factory gross margin of the three factories which were first put into operation in Vietnam, have outperformed the three factories put into operation subsequently. According to the rigorous technological authentication conducted by the Company, there is still room for continuous growth and optimization of these factories. Meanwhile, leveraging the actual operational experience of the first three factories in Vietnam, the Group will accelerate the production efficiency of the other factories in Vietnam so as to enhance the consolidated gross margin. The first phase of the facility in Hung Yen Province, Vietnam, which mainly applies seamless knitting technology, officially commenced operation in April 2021 and active recruitment is still in progress. As for domestic operations in China, in order to enhance operational efficiency and optimize its cost structure, the Group surrendered parts of the leased factory in Shenzhen and made a write-off of fixed assets of approximately HK$61.1 million during the year. The aforementioned relocation of the Shenzhen production base to Zhaoqing will further help the Group achieve an optimized production capacity allocation in the long run. The vaccination rates of eligible employees at the Group's production bases in Shenzhen and Hai Phong reached approximately 95% and 90%, respectively, which, to a large extent, will protect the health of employees and the safety of the working environment, while maintaining stable production operations. From the end of 2021 to the beginning of 2022, there were temporary closures and lockdown measures implemented in Shenzhen and Vietnam, respectively, due to a further outbreak of the Pandemic. Thanks to the rapid response of the Shenzhen and Vietnam governments, the Pandemic was soon brought under control. The flexible deployment of human resources by its local managerial team also enabled the Group to minimize the impact of the Pandemic on its production capacity and avoid compromising its ability to fully capture the strong order demand from international and domestic brand partners.Insist on innovation-driven development, to thrive on vast experience, and expand multiple business segments to usher in a golden era of development Faced with a combination of various factors, the industry is up against challenges such as tight supply chains and rising raw material costs, and is undergoing a reshuffle. In this context, Regina Miracle's comprehensive competitiveness in terms of technological barriers, world-leading product innovation capabilities and highly viscous brand-partner relationships established over the years will be further highlighted, laying a solid foundation for future growth and ushering in a golden era of development.Continuous upgrading of core technologies and formation of a win-win and mutually beneficial strategic cooperative relationship with loyal brand partnersOver the years, Regina Miracle has adhered to its IDM business model, supported by its global industry-leading product innovation capabilities. The Group has formed a diversified technological matrix based on three core technologies: computer-aided mold design and production, 3D compression molding, and seamless bonding, with applications spanning various fields such as intimate wear, sports and consumer electronics. The uniqueness, leadership, malleability and versatility of the core technologies allow for a high degree of cross-use by different brand partners in different categories, as well as the ability to cater to the different positioning and needs of each brand and to continue to develop unique and innovative products for the Group's brand partners. This, coupled with the Group's insistence on a mutually beneficial win-win strategy, consistent quality and a high degree of flexibility, has won the trust and viscousness of various brand partners in terms of Regina Miracle's IDM positioning, which will help strengthen the Group's market position in the long run after the industry reshuffle. The Group has also strived to foster and steer the industry trends by continuously strengthening and upholding its technological barriers, registering patents and trademarks for its unique technologies, defining new standards for the industry and providing consumers with a more direct and in-depth understanding of high value-added products, leading the development trend and demand of the market.Realization of the Five-Year Plan blueprint for Fiscal 2022-2026 well underway, promote stability and diversified growth with solid foundationAfter several years of significant investment, Regina Miracle has laid a solid foundation for its future development. In order to lead the Group to a new chapter of development and a brighter future, after giving careful consideration to and conducting a comprehensive review of the market and the businesses, the management has formulated a brand-new five-year plan for Fiscal 2022-2026 focusing on the following areas:I. Drive steady revenue growth: Adhere to the IDM business model to drive steady growth in sales through innovation and R&D, and accelerate the expansion into the PRC market;II. Margin expansion: Continue to develop high value-added and innovative products with better margin, while enhancing management and production efficiency, improving operating leverage as revenue grows and effectuating faster growth in target earnings than in revenue; and III. Sound financial position: Maintain healthy operating cash flows and control capital expenditures through the above measures in order to gradually lower gearing ratio in the medium and long terms, following the completion of the Group's capex intensive investment phase in Northern Vietnam over the last few years.During the year under review, the Group was successful in realizing its target blueprint for Fiscal 2022 set out in its five-year plan, and on the basis of achieving high sales growth, its efficiency and profit margin increased, laying foundation for the Group's medium- and long-term healthy financial position. Based on currently foreseeable orders, the Group remains optimistic that the business will continue to perform well in the first half of 2023. Looking forward, despite numerous uncertainties in the macro-environment, the Group will endeavor to comprehensively achieve the established goals in the five-year plan, fully utilize tailwinds from the advantages of the environment and itself, take stock of the situation and remain flexible to respond, and drive steady rise in the Group's business.At the business level, the Group's future growth will be driven by the four business segments of intimate wear, sports products, consumer electronics components products and footwear:-- The intimate wear business is expected to continue growing steadily. The growth in the intimate wear segment is mainly attributable to the expansion of individual brand partners and the increase in market share of key brand partners, underpinned by the development of innovative craftsmanship products and the product expansion into several sub-categories.-- Growing share of the sports business, with innovative craftsmanship leading the rapid growth in industry demand. In recent years, international brands have become increasingly aware of the importance of the female sports market, of which sports bras are a core product which still has huge development potential. Owing to its foresighted planning several years ago, the Group's strategic partnerships with several leading global brands have become increasingly steadfast and the addition of a number of fast-growing new brands has formed an ideal brand partner portfolio and helped the Group to grasp the growth momentum of the sports intimate wear industry. Meanwhile, Regina Miracle's innovation and R&D capabilities have led to the evolution and upgrading of leggings in the sports segment, significantly enhancing their functionality and comfort, etc. Demand for products in the sports leggings segment is growing significantly and is expected to replicate the growth trajectory of sports bras.-- The consumer electronic components business is showing a trend of diversified development for the coming years to build a more stable product and brand partner portfolio. With the emergence of the "Metaverse" concept, more emphasis is being placed on consumer electronic softgoods products offering a more comfortable, skin-friendly wearing experience that is suitable for prolonged use. The Group is well positioned to apply its innovative craftsmanship and three core technologies in the consumer electronics segment, conducive to develop market-leading products. In addition to the existing international brand partners, the Group introduced domestic leading brand partner during the year with the opportunities for expansion of product categories, driving the growth of consumer electronics components segment of the Group in the coming years. Relevant brand partners have been promptly deploying in this field as well as lengthening their product cycles, resulting in relatively high sales visibility. The Group actively plans and responds to the changing high technology product market through implementing a strategy to diversify its brand partners and product portfolios, laying a flexible and stable foundation for the development of consumer electronics components business.-- The footwear business will continue its steady growth on the current basis. The Group is currently focused on working with an American casual footwear brand. With years of joint development, the partners will continue to go hand in hand and maintain the growth momentum in the foreseeable future.A maturing multi-regional production capacity layout, with advantages of Vietnam as a production base in the global supply chain becoming more prominentIn order to enhance its core competitive advantages, the Group is committed to multi-regional production capacity deployment, bolstering the growth of its export business with its production bases in Vietnam, while promoting the development of the PRC market by leveraging the production bases in China.Against the backdrop of the increasing complexity of global competition and cooperation, Vietnam has become highly sought after by global manufacturing enterprises due to its status as a member state of various trade agreements, its advantages in terms of population size, labor costs and cultural standards, and the local government's commitment to ensuring stable operations for supply chain enterprises. After around six years of strategic deployment for overseas production capacity layout and team cultivation, the Group's production capacity in Vietnam now presents multiple advantages in terms of scale, power, agility and high-quality output. Meanwhile, the implementation of digital management has enabled the Group's deployment of its production capacity to be more coordinated and agile. In addition, Regina Miracle has gradually refined its supply chain localization, including spearheading its core suppliers to accelerate the deployment or expansion of local production capacity in Vietnam, thereby shortening the delivery cycle, improving response time and forming an efficient local problem-solving mechanism, and ultimately optimizing integrated cost efficiency. The Group's competitive advantages are becoming more evident as the industry supply undergoes consolidation.In respect of its business development in the PRC, the Group has also improved production efficiency by promoting automation and digitalization to address the needs of production capacity, strengthening supply chain management, developing local suppliers and ensuring fast delivery, as well as planning production capacity deployment in advance. With the relocation of the Group's R&D center and production base from Shenzhen to the new industrial park in Zhaoqing New District in the Greater Bay Area in phases during the period between mid-2023 and the end of 2024, to produce mainly intimate wear, sports apparel and consumer electronics components with its leading and innovative craftsmanship, the Group will be better positioned to collaborate with international brand partners in tapping the PRC market and to step up efforts to explore new opportunities with emerging online brands in the domestic market and across other channels.Integrating technological innovation and digital intelligence to accelerate penetration into the PRC marketThe intimate wear market in China is characterized by low brand concentration, with most of the existing brands offering a single or relatively narrow product range, while consumer demand is growing rapidly across product segmentation and functional specialization. This industry trend, coupled with the rapid development of e-commerce in the PRC, provides an excellent opportunity for all brands with potential to expand their market share.-- Entered into strategic partnership with Tmall Intimate Wear and TMICIn order to better serve our brand partners that make sales in the PRC and to more quickly identify and address the latest market trends and consumer needs, the Group entered into a strategic partnership with Tmall Intimate Wear and Tmall Innovation Center ("TMIC") on 20 May 2022. TMIC has gained insights into consumer aspirations and feedback from mass purchase activities, forward-looking trend data analysis and a deep understanding of consumer behavior, which helps the Group to carry out specialized and precise R&D, translate consumers' demands into concrete technological solutions and integrate them into end products. Through the joint efforts of the three parties, the Group hopes to achieve the goals of incubating highly reputable and consistently best-selling products that could set new trends, create innovative technology IP, and establish industry standards for specific categories, thereby promoting the healthy and orderly development of the intimate wear market in the PRC.--Established a joint venture with Victoria's Secret to Seize the Opportunities in the PRC marketThe establishment of a joint venture ( "VS China" ) between Regina Miracle and Victoria's Secret & Co. ( "Victoria's Secret" ) in January 2022 also marks a strategic move towards the Group's layout in the PRC market. As the world's largest international intimate wear brand, Victoria's Secret boasts strong consumer brand awareness and mature retail operation and marketing capabilities in the PRC market, which highly complement the Group's strengths in product innovation, research and development and manufacturing, as well as its deep insights into the PRC market and consumers. The joint venture will focus on three main dimensions encompassing product, supply chain and business operations, strengthening the brand in all aspects to better cater for the PRC market. Recently, the range of products that the Group has developed with VS China for the PRC market have been well-received. The first stage of the transformation of the brand's online business has already yielded remarkable results, in which the first launch of "Double-Size 'Jelly-Striped' Bra Top" has seen cumulative sales of more than 250,000 units within four months, while the brand's impact and performance has gradually become more consistent, which clearly demonstrates the synergies between VS China and Regina Miracle in setting the trend for the market.ESG is incorporated into the supervisory responsibilities of the Board and the Group is committed to achieving the 2030 Sustainable Development GoalsIn Fiscal 2022, Regina Miracle officially incorporated ESG into the supervisory responsibilities of the Board, and established an environmental, social and governance committee (the ESG committee), led by the Group's Chief Operating Officer, to strengthen the Board's role in overseeing ESG policies, and facilitate better planning for the management and achievement of the Group's sustainability goals. During the year, the Group decided upon six key issues of concern, including climate action, life on the land, clean water and sanitation, responsible consumption and production, decent work and economic growth, and gender equality, based on the United Nations' 2030 Sustainable Development Goals. In response to these six major directions, the Group has set itself four goals for 2030, namely carbon reduction, waste management, sustainable innovation, and people and community. Regina Miracle will continue to be committed to promoting environmental and social sustainable development, creating long-term value for all stakeholders and assuming its social responsibility with a responsible attitude.Mr. Hung concluded: "With years of perseverance in innovative design and manufacturing, Regina Miracle has successfully established solid technological barriers and developed market-leading products. In the future, the Group will continue to give full play to its advantages in various aspects and pursue win-win situations with its brand partners. At the same time, the Group will continue to be committed to fulfilling its social responsibilities and contributing to the enhancement of the environment, employees and the community, thereby achieving sustainability and delivering long-term value for shareholders and stakeholders. The Group's encouraging performance during the year is attributed to the tireless efforts and dedication of the management team and colleagues. The Group would also like to express its sincere gratitude to the brand partners, supply chain partners and the shareholders for their unwavering support in overcoming the challenges created by the Pandemic. The management is confident that the Group can sustain its growth momentum in the future, further achieve the goals set out in its five-year plan, and move closer towards a golden era of development."About Regina Miracle International (Holdings) LimitedFounded in Hong Kong in 1998, Regina Miracle International (Holdings) Limited is a global leader in the intimate wear manufacturing industry. Adopting the innovative design manufacturer ("IDM") business model, Regina Miracle offers its world-renowned brand partners diverse products, including intimate wear, sports products, consumer electronics components, bra pads and moulded products, footwear and fabric masks. The Group has two strategic strongholds - its R&D and production base in Shenzhen, China, and a major production base in Vietnam, where the Group has expanded production capacity since 2016. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
E.Design Insurance and Eisai Enter Into Business Alliance JCN Newswire

E.Design Insurance and Eisai Enter Into Business Alliance

TOKYO, Jun 28, 2022 - (JCN Newswire via SEAPRWire.com) - E.design Insurance Co., Ltd., a direct non- life insurance company of the Tokio Marine Group, and Eisai Co., Ltd. announced today that both companies have entered into a business alliance agreement aiming to realize a society where people can safely enjoy driving for a longer period of their lives in anticipation of the advent of super-aging society, under the theme of "Improving Brain Health (brain performance) for Safe Driving." EDSP, as an Insurtech (a term coined by combining insurance and technology) company which promotes "co-creation of a world without accidents" with customers and other companies or local governments, and Eisai, which aims to build a dementia ecosystem through coexisting with various industries and organizations to remove the diverse anxieties of each individual, both will take this business alliance as an opportunity to promote safe driving and extend driving life, thereby contributing to solving the issues associated with an aging society.The initiatives planned under the alliance are as follows.1. Providing an opportunity to check brain healthThe privilege of using "NouKNOW", the digital tool for self-assessment of brain health distributed by Eisai, will be offered to customers who have purchased the "&e", automobile insurance of EDSP (Scheduled for July 2022). With "NouKNOW", brain health is measured quantitatively through a simple card test using smartphone or other devices, evaluating psychomotor function, attention, learning and memory, and working memory. When driving a car, the human brain processes a variety of information, such as road conditions, traffic volume, or the route to a destination, and makes instantaneous judgements repeatedly. Introducing "NouKNOW" is intended to promote safe driving and encourage people to become more aware of their brain health on a daily basis, which is thought to contribute to human judgment while driving.2. Jointly developing solutions for maintaining and improving brain healthEDSP and Eisai will jointly develop solutions that help maintain and improve brain health, by leveraging Eisai's experience and expertise, to enable customers to drive safely for a longer period of time in their lives. Both companies aim to create new solutions, including the development of training contents utilizing data on the characteristics of daily driving behavior and data on brain functions, and the development of a service, targeting customers whose brain health has declined or whose risky behavior has increased, to compile an integrated report on their brain performance and safe driving capability by utilizing the driving score provided by "&e" and the "NouKNOW" score, that allows customers to share the results not only with themselves but also with their families.About "&e"The "&e", co-creation-type auto insurance, provides benefits such as support services for safe driving tailored to each customer by linking IoT sensors and smartphones, in order to reduce the number of customers involved in accidents by even one.For more information about the "&e", please visit www.e-design.net/About "NouKNOWTM""NouKNOW" (non-medical equipment) is a self-checking tool of brain health (brain performance) developed by Eisai based on the algorithm created by Cogstate, Ltd. (Headquarters: Australia) for which Eisai holds the rights for exclusive development and commercialization worldwide. It is not a tool for the prevention and diagnosis of diseases, but therefore for the purpose of self-checking brain performance in order to raise health awareness. This digital tool allows users to self-assess independently evaluating psychomotor function, attention, learning and memory, and working memory in a short time frame (approx.15 minutes) through a simple card test using smartphone or other devices.For more information about "NouKNOW", please visit https://nouknow.jp/ (Japanese only) About E.design Insurance Co., Ltd.E.design Insurance Co., Ltd. is an Insurtech company* of the Tokio Marine Group with the mission of "not only supporting peace of mind in the event of an accident, but also creating a world without accidents, together with our customers." E.design Insurance Co., Ltd. is taking on the challenge of realizing a "world without accidents" through projects such as the "Safe Drive With," a project to reduce accidents using driving data with "&e" and various data on traffic safety, and the "+Machi (Pla-Machi)," a donation program for community-based initiatives to reduce traffic accidents and promote traffic safety, together with customers, local governments, and companies that support our aim of "creating safety through data. E.design Insurance Co., Ltd. will continue to work with its customers to create a new form of insurance industry.*For more information on Insurtech insurer, please see Tokio Marine Holdings, Inc. News Release: bit.ly/3ylN7b0About Eisai Co., Ltd.The Eisai's Corporate Philosophy is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Philosophy (also known as human health care (hhc) philosophy), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. Under the medium-term business plan "EWAY Future & Beyond", which began in April 2021, Eisai is expanding its main role in healthcare, that is, we should contribute not only to people in the medical domain but also to people in the daily living domain. We aim to evolve into an hhceco (hhc philosophy + eco-system) company that empowers people "to realize their fullest life" by creating solutions based on science and data through building an ecosystem in collaboration with other industries.In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), with working on various activities together with global partners. Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)
More
SEAPRWire Releases Branding-Insight Program, Empowering Communicators to Further Understand Audiences SeaPRwire

SEAPRWire Releases Branding-Insight Program, Empowering Communicators to Further Understand Audiences

Singapore, June 28, 2022 – SEAPRWire, a leading earned media communications management platform in Asia, today announced the launch of their Branding-Insight Program, which will empower PR and communications professionals to further understand their audiences while doing press release distribution. With Branding-Insight, clients can now tap into a network of over 80,000 journalists, editors, magazines and online media outlets, together with 300 million followers of KOLs all in one platform. Branding-Insight is built on the foundation of SEAPRWire’s media and influencer database to help communicators effectively target, pitch and build stronger relationships with the media. “SEAPRWire’s strong influence in East Asia and Southeast Asia is built upon our customer satisfaction,” said YQ Tang, CMO at SEAPRWire. “This program allows all enterprises to stay relevant and engaged with their customers and stakeholders. We have confidence that with Branding-Insight Program, we will empower our clients to solve the key challenges PR and communications professionals are facing.” Complete with AI-Driven technology, SEAPRWire’s Branding-Insight Program allows users to easily discover the most relevant media and KOLs to their business, which will empower communicators to personalize pitches for improved earned media results. Branding-Insight Program is now available for regions of Japan, PRC China, Korea, Hong Kong (China), Singapore, Vietnam, Thailand, Malaysia, Indonesia and Philippines. 3 weeks ago, SEAPRWire and EQS Group (www.eqs.com) announced a media partnership in Asia (East and Southeast Asia). The partnership includes media list expansion and media outreaching business cooperation. The partnership covers mainland China, Hong Kong, Singapore, Thailand, Vietnam, Malaysia, Indonesia, and the Philippines. Both parties look forward to further cooperation in the future. About SEAPRWire SEAPRWire (https://www.seaprwire.com/) is a leading global provider of wire distribution services to media relations and marketing communications professionals. SEAPRWire’s platform allows clients to identify key factors of their press releases and measure meaningful impact. It has a strong media network in Southeast Asia, indexing news from thousands of worldwide sources. SEAPRWire’s media network support multi-lingual press release distribution, including English, Chinese, Vietnamese, Thai, Malay, Indonesian, Filipino and more. Media Contact Tina Lee, PR manager cs@seaprwire.com https://seaprwire.com SOURCE: SEAPRWire
More
Apptio reinforces commitment to Asia with strategic hire ACN Newswire

Apptio reinforces commitment to Asia with strategic hire

SINGAPORE, Jun 24, 2022 - (ACN Newswire via SEAPRWire.com) - Apptio, the leading provider of technology business management (TBM) applications, has appointed Tarun Kumar Kalra as Regional Vice President - Asia. Tasked with strengthening and establishing new strategic engagements in the region to help organizations make informed, data-driven technology business decisions, Tarun will focus on creating incremental value for Apptio's customers and partners and expanding the company's presence across Asia.Tarun Kumar Kalra"Tarun joins us at a time of exceptional possibility in Asia and we are leaning on his experience and leadership to grow Apptio's presence across the region. CIOs are being asked to do more with less, and to be accountable for their spending. Apptio equips them with the data and insights to better manage their IT investments and align them to business outcomes, through the implementation of the Technology Business Management (TBM) and FinOps disciplines," Ben Allard, Apptio Vice President and General Manager, Asia Pacific remarked. "Tarun will be instrumental in leading the execution of Apptio's vision and the adoption of TBM, FinOps and agile disciplines in the region,"Kalra observes that, "Asian economies continue to witness consumption-driven growth, fueled by governmental and private enterprises driven capital expenditure (CapEx) expansion cycles. Organizations that are 'born in the cloud' are altering customer engagement models and technology consumption patterns. For that reason, cloud computing is the cornerstone of technology innovation, ensuring organizational resilience."He adds, "Clients are seeking frictionless engagement models to give them the ability to scale new products and services to support their market expansion strategies. That requires nimble and agile technology organizations."Kalra expects growth in the technology sector to continue with further advances being made in digital banking, healthtech, insurtech, and ecommerce. He says "Such organizations, along with large enterprises and government departments are grappling with ballooning technology costs while struggling with a limited view on a single pane and single source of truth on their returns on technology investments. Apptio is uniquely positioned with a proven solution to help these organizations derive deeper financial accountability and effectively allocate resources to areas of greater ROI and innovation."About ApptioApptio gives you the power of trusted, actionable insights to connect your technology investment decisions to drive better business outcomes. More than 60 percent of Fortune 100 enterprises trust Apptio to manage spend across the entire IT portfolio and beyond, so they can focus on delivering innovation. Apptio automatically ingests and intelligently structures vast amounts of enterprise and technology-specific spend and operational data. Apptio enables users across disciplines to report, analyze, plan, and govern their investments collaboratively, efficiently, and with confidence. Learn more at Apptio.com.NOTES TO EDITORS1. Apptio's solutions help IT leaders in large, complex enterprises and governments better manage the business of IT, so they can deliver better products and services, and improve the customer's experience.2. IT leaders need better insights into their technology portfolio and spending to be able to make real-time decisions and align their IT investments to business value. Apptio empowers them with the data and insights to appropriate their resources wisely, elevating them to be accountable at the board level.3. With Apptio, it is easier to make decisions when managing cloud services - whether multi-cloud or hybrid - reduce waste and avoid cloud overspend, with a view to improve operational expense (OpEx) and capital expenditure (Capex) management.4. Over the past few years, Apptio has expanded their presence in Asia to support customers on the ground in Singapore, Indonesia, Malaysia, the Philippines, and Vietnam, where there is hypergrowth in companies moving to the cloud, driving agile transformation and aiming for greater business agility.5. To support the customers and partners in the region, Apptio has doubled its number of employees in Southeast Asia, nearly half of whom are women. The company is justly proud of its track record of hiring for diversity and inclusion in the region.MEDIA CONTACTWindy OktavianiAssociate, PINPOINT PRwindy@pinpointpr.sgWhatsApp: +62 811 910 9266 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Eisai Publishes Potential Economic Value of Investigational Lecanemab in Peer-Reviewed Neurology and Therapy Journal JCN Newswire

Eisai Publishes Potential Economic Value of Investigational Lecanemab in Peer-Reviewed Neurology and Therapy Journal

TOKYO, Jun 22, 2022 - (JCN Newswire via SEAPRWire.com) - Eisai Co., Ltd. today announced publication of results from an early phase evaluation that aimed to estimate potential economic value of its investigational anti-amyloid-beta (Abeta) protofibril antibody lecanemab in people living with early Alzheimer's disease (AD) using a validated disease simulation model, AD Archimedes Condition Event (AD ACE) model1,2,3 from the healthcare payer and societal perspectives in the United States, in the peer-reviewed journal Neurology and Therapy. This is the second publication of lecanemab's potential value. It follows the evaluation of the long-term health outcomes using simulation modeling of lecanemab published in Neurology and Therapy in April 2022.4 While the healthcare payer perspective focuses on direct care costs (e.g., outpatient and inpatient services, medications, intervention costs, nursing home and home healthcare services), the societal perspective further considers societal costs (e.g., productivity loss and informal care costs). As reported in the previous publication, it was suggested that compared to standard of care* (SoC), individuals treated with lecanemab in addition to SoC (lecanemab+SoC) may potentially experience slower disease progression to mild, moderate and severe AD from baseline by 2.51, 3.13 and 2.34 years on average, respectively. The preliminary results of this model-based simulation could possibly translate into additional quality-adjusted life years (QALY**) and reduction in the formal and informal care costs***. Additionally, the AD ACE model framework used in this study allowed assessment of the potential value of lecanemab in different scenarios and sensitivity analyses, including the impact of patient subsets, alternative treatment stopping rules**** and potential dosing regimens as well as major sources of uncertainty. Eisai is committed to conducting and sharing these types of clinical and socioeconomic analyses to establish trust as we work to potentially bring lecanemab to people living with early AD who have confirmed presence of amyloid pathology in the brain. To that end, Eisai would like to provide a common foundation for stakeholders' discourse regarding the potential clinical and socioeconomic value of lecanemab from the societal perspective, not to assign a price for lecanemab at this time. This model-based simulation was conducted using the results of a Phase 2b clinical trial (Study 201) evaluating the efficacy and safety of lecanemab for early AD with confirmed amyloid pathology as well as published literature. It also estimated the potential economic value of lecanemab+SoC over a broad range of willingness-to-pay thresholds from $50,000 to $200,000 per QALY gained as recommended by the Institute for Clinical and Economic Review (ICER)*****. Lecanemab+SoC was predicted to result in a gain of 0.61 QALYs and a decrease in total non-treatment costs of $8,707 per person from the healthcare payer perspective (Societal perspective: 0.64 QALYs gain and $11,214 decrease) compared to the SoC for patients with early AD who have confirmed presence of amyloid pathology. The potential annual value-based price (VBP) of lecanemab was estimated at $9,249 to $35,605 (Societal perspective: $10,400 to $38,053) based on this early economic assessment. ICER's value framework5 indicates that value cannot be wholly derived from measures of clinical and cost-effectiveness, so contextual considerations and an examination of other benefits and disadvantages are also added into the framework when assessing long-term value. This may lead to using the societal perspective and higher end of the broad range of willingness-to-pay threshold in estimating the justifiable price of lecanemab, given the large societal burden of AD relative to direct healthcare costs. Many people living with AD received informal care from their family and friends totaling more than 16 billion hours of unpaid care valued at $271.6 billion in the U.S. in 2021.6 These predicted and simulated findings suggest that early treatment with lecanemab may reduce these costs and economic burdens, and provide insights for healthcare decision-makers regarding the potential clinical and socioeconomic value of lecanemab. The Phase 3 lecanemab Clarity AD data will soon be available to inform the model inputs and refine the findings. In the event that lecanemab receives the U.S. Food and Drug Administration's (FDA) approval, Eisai may determine a VBP using this framework along with other considerations, such as affordability, health system sustainability, etc. "Eisai's goal is to create therapies, such as our investigational anti-amyloid beta protofibril antibody lecanemab, that may help impact the anxieties of people living with Alzheimer's disease and their families. For Alzheimer's disease, it is important to evaluate the holistic value of therapies taking into account not only medical costs but also the immense societal costs," said Ivan Cheung, Senior Vice President, President Neurology Business Group and Global Alzheimer's Disease Officer, Eisai Co., Ltd., Chairman and CEO, Eisai Inc. "As part of Eisai's commitment to our human health care mission, trust and transparency, we will continue to publish data and information about lecanemab and look forward to sharing the results of the lecanemab confirmatory Phase 3 Clarity AD clinical trial this fall." Eisai completed lecanemab's rolling submission of a Biologics License Application (BLA) for the treatment of early AD to the FDA under the accelerated approval pathway in May 2022. The Clarity AD Phase 3 clinical study for lecanemab in early AD is ongoing and completed enrollment in March 2021 with 1,795 patients. The readout of the primary endpoint data of Clarity AD will occur in the fall of 2022. The FDA has agreed that the results of Clarity AD, when completed, can serve as the confirmatory study to verify the clinical benefit of lecanemab. Dependent upon the results of the Clarity AD clinical trial, Eisai may submit for full approval of lecanemab to the FDA during Eisai's fiscal year 2022, which ends in March2023. In Japan, in March 2022, Eisai initiated submission of application data to the Pharmaceuticals and Medical Devices Agency (PMDA) under the prior assessment consultation system with the goal of obtaining early approval for lecanemab, and aims to file for the manufacturing and marketing approval based on the results of Clarity AD during Eisai's fiscal year 2022. Also, in Europe, based on the results of the Clarity AD study, Eisai plans to submit a new drug application in fiscal year 2022. This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that such an investigational agent will successfully complete clinical development or gain health authority approval. * Standard of Care (SoC) for AD currently consists of lifestyle modifications and pharmacologic treatment of symptoms.** The quality-adjusted life year (QALY) is a measure of the value of health outcomes. Since health is a function of length of life (i.e., quantity) and quality of life (QOL), the QALY was developed as an attempt to combine the value of these attributes into a single index number. One QALY equates to one year in perfect health. QALY scores range from 1 (full health) to 0 (dead). For example, a new intervention may increase length of life by 3 years and improve quality of life by 70% (QALY score of 2.1) compared to an existing intervention that may increase length of life by 3 years and only improve QOL by 50% (QALY score of 1.5), the incremental QALY for this new intervention will be 0.6 QALYs.*** Formal and informal care costs do not include lecanemab drug cost.**** Alternative treatment stopping rules were explored in scenario analyses where treatment with lecanemab was stopped after a fixed duration of 1.5, 3 and 5 years.***** ICER is a non-profit research organization in the U.S. that evaluates the evidence on the clinical and economic value of prescription drugs, medical tests, devices and health system delivery innovations. 1 Kansal AR, Tafazzoli A, Ishak KJ, Krotneva S. Alzheimer's disease Archimedes condition-event simulator: Development and validation. Alzheimers Dement (NY). 2018;4:76-88. Published 2018 Feb 16. doi:10.1016/j.trci.2018.01.001.2) Tafazzoli and Kansal. Disease simulation in drug development, External validation confirms benefit in decision making. The Evidence Forum. 2018. bit.ly/3NgEeDD(3) Tafazzoli A, Weng J, Sutton K, et al. Validating simulated cognition trajectories based on ADNI against 436 trajectories from the National Alzheimer's Coordinating Center (NACC) dataset. 11th edition of Clinical Trials on 437 Alzheimer's Disease (CTAD); Barcelona, Spain: 2018.(4) Tahami Monfared AA, Tafazzoli A, Ye W, Chavan A, Zhang Q. Long-Term Health Outcomes of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation Modeling. Neurol Ther 11, 863-880 (2022). https://link.springer.com/article/10.1007/s40120-022-00350-y.(5) ICER Value Framework 2020-2023. 2022. bit.ly/39HjYO3(6) Alzheimer's Association. 2022 Alzheimer's Disease Facts and Figures 2022 Available from: bit.ly/3bkCR9VMedia Inquiries:Public Relations Department,Eisai Co., Ltd.+81-(0)3-3817-5120 Eisai Inc. USLibby HolmanLibby_Holman@Eisai.com201-753-1945 Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)
More
The Mechanism of Action of SinoMab’s Flagship Product SM03 is Successfully Published in the Journal of Immunology, a Reputable Journal on Immunology in the U.S. ACN Newswire

The Mechanism of Action of SinoMab’s Flagship Product SM03 is Successfully Published in the Journal of Immunology, a Reputable Journal on Immunology in the U.S.

HONG KONG, Jun 21, 2022 - (ACN Newswire via SEAPRWire.com) - SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong listed biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of innovative therapeutics for the treatment of immunological diseases, primarily mAb-based biologics, today announced that, on 10 June 2022, the mechanism of action of its flagship product SM03 (Suciraslimab) is successfully published in the Journal of Immunology, a reputable journal on immunology in the US (link to the paper: https://www.jimmunol.org/content/early/2022/06/10/jimmunol.2100820 ).Figure: Mechanism of Action of SM03 (Suciraslimab)The Journal of Immunology (the JI), founded in 1916 and managed and published by the American Association of Immunologists, is the world's leading peer-reviewed journal in the field of immunology, with a 5-year impact factor of 6.029 (Journal Citation Reports 2020), and publishes the latest immune-related findings in basic and clinical research in the field of immunology. It also publishes the latest research papers in the field of immunology, including cellular immunology, immunochemistry and molecular immunology, immunogenetics and immunomodulation, immunopathology and clinical immunology, immunopharmacology, microbial immunology, oncology and transplantation.The Company's flagship product SM03 (Suciraslimab) is a potential global first-in-target mAb against CD22 for the treatment of rheumatoid arthritis (RA). The patient enrollment for the Phase III clinical trial in China has been completed by the end of 2021, with a total of 530 subjects recruited. The trial is a multi-centre clinical study led by Peking Union Medical College Hospital of the Chinese Academy of Medical Sciences, with clinical centres in 44 hospitals including Gulou Hospital of Nanjing University School of Medicine, the Second Hospital of Harbin Medical University and the First Hospital of Shanxi Medical University. The Company expects to lock the database at the end of June this year, read out the results of the Phase III clinical trial data in early August and will have biologics license application (BLA) in 2023. In addition, the development of Suciraslimab has also received support from the 863 Program, the "12th Five-Year Plan" and the "13th Five-Year Plan" for development of major new drugs, as well as the green channel for "prioritized review and approval" by the Center for Drug Evaluation (CDE). Previously, a phase II clinical trial led by Peking Union Medical College Hospital has demonstrated the efficacy and safety of Suciraslimab for the treatment of RA.The Company's flagship product Suciraslimab is a potential global first-in-target mAb against CD22 for the treatment of rheumatoid arthritis. The core competitive advantage of this product over the standard therapies currently on the market is its novel and unique mechanism of action, which ensures that Suciraslimab is comparable to other products in terms of efficacy, while having significant advantage in terms of safety, which is a major concern for patients on long-term medication for autoimmune diseases.Under normal operation of human's immune system, B-cell receptor (BCR) pathway would be activated and create strong signals in response to foreign ("non-self") antigens and trigger a series of B-cell immune responses. To differentiate from our "self" antigens, our body would recruit molecules, like SHP-1, to inhibit or reduce BCR-induced signaling, thereby suppressing B-cell immune responses. We suggested that the recruitment of these molecules such as SHP-1 could be achieved by conversion of cis-binding CD22 to trans-binding CD22, thus suppressing relevant immune responses. Due to ageing or genetic predisposition, patients with autoimmune diseases such as RA are unable to convert cis-binding CD22 to trans-binding CD22, and are thus unable to recruit immunosuppressive molecules such as SHP-1 to inhibit or reduce the transmission of antigenic stimuli from B-cell receptors to B-cells, which then generate a series of immune responses, such as the secretion of large amounts of antibodies to attack autoantigens. Our flagship product, Suciraslimab, can facilitate the conversion of cis-binding CD22 to trans-binding CD22, forming a stable CD22 trans-binding structure, thereby restoring the tolerance of B-cells to autoantigens and inhibiting a series of relevant immune responses by B cells to attack the body.Historical data shows that Suciraslimab has a significant safety advantage compared to other products with comparable efficacy currently available in the market. Existing RA therapies include traditional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) such as methotrexate (MTX), biologic DMARDs (bDMARDs) targeting tumour necrosis factor (TNF), interleukin (IL)-6 receptors and other targets, as well as targeted synthetic DMARDs (tsDMARDs) such as Janus kinase (JAK) inhibitors and other small molecule drugs, all of which have played an important role in the remission of RA patients. However, most of the mechanisms of action of existing RA therapies will result in the depletion or death of B cells, which can have a series of side effects on human's autoimmune system, thus posing a long-term risk for patients with autoimmune diseases who require long-term medication, as the weakening of the immune system will naturally lead to the development of other debilitating diseases. In contrast, the mechanism of action of Suciraslimab is very different from that of existing therapies on the market. We only inhibit the B-cell related immune response by altering the binding of CD22 and recruiting related inhibitory molecules. Suciraslimab only inhibits the autoimmune response by regulating the function of B-cells and does not damage the B-cells and does not affect the normal function of B-cells in the immune system. Therefore, Suciraslimab has a significant safety advantage over other products currently available on the market.The autoimmune disease drug market has been touted as the next gold mine after oncology drugs. As the "king of drugs" in the world, Humira has topped the global drug ranking for eight years with sales of US$19.832 billion in 2020, making other drugs "bow down". Globally, pharmaceutical giants are focusing on the research and development of drugs in the rheumatic immune field, with the most prominent ones including Pfizer, Novartis, Johnson & Johnson and AbbVie, all with more than a dozen products in development or marketed in their respective pipelines. The global autoimmune disease drugs market is valued at US$113.7 billion in 2018 and is expected to reach US$152.3 billion by 2023 at a CAGR of 6.0%. The market for autoimmune disease drugs in China is expected to grow from RMB13.4 billion in 2018 to RMB37.7 billion in 2030 at a CAGR of 23%. Driven by the global trend of innovation, R&D in rheumatic immune field in China is also gaining momentum. As a leading pharmaceutical innovator in China, Hengrui Pharma has also adopted a strategy of early development, target optimization and expansion of indications in the rheumatic immune field, aiming to fully capitalize on the rapid development of the autoimmune disease market in China. This indicates that SinoMab's mission and vision to become a global leader in innovative therapies for immune and other debilitating diseases are in line with the development trend of the entire pharmaceutical industry. In the foreseeable future, it is believed that SinoMab will help more and more patients suffering from autoimmune diseases and become a leading global biopharmaceutical company focusing on innovative therapies for autoimmune diseases.In addition to its flagship product Suciraslimab, the Company's core product SN1011 has an expanding scope of indications and continues to receive regulatory approval for new drug applications in China and abroad, and also expects to rapidly initiate Phase II clinical trials for pemphigus vulgaris (PV), multiple sclerosis (MS), systemic lupus erythematosus (SLE) and neuromyelitis optica spectrum disorder (NMOSD) this year. SinoMab also dosed first healthy subject in Phase I clinical trial of its major product SM17 in the U.S. in June 2022. By targeting upstream mediators of the Th2 inflammatory cascade, SM17 is able to control inflammatory airway diseases such as asthma caused by the immune cascade at a relatively early stage and is expected to benefit a large number of patients with severe uncontrolled asthma by satisfying unmet medical needs.About SinoMab BioScience LimitedSinoMab BioScience Limited (stock code: 3681.HK) is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The Company's flagship product SM03 is a potential global first-in-target mAb against CD22 for the treatment of rheumatoid arthritis (RA) and is currently in Phase III clinical trial for RA in China, which has been recognized as one of the significant special projects of Significant New Drugs Development of the Twelfth Five-Year Plan Period and the Thirteenth Five-Year Plan Period. In addition, the Company possesses other potential first-in-target and first-in-class drug candidates, some of which are already in clinical stage, with their indications covering rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), pemphigus vulgaris (PV), non-Hodgkin's lymphoma (NHL), asthma, and other diseases with major unmet clinical needs. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More

The 5th Brasil Investment Forum Brought Together Global Business Leaders, Actively Promotes the High-quality Investment Opportunities in Brazil

SHANGHAI, Jun 20, 2022 - (ACN Newswire via SEAPRWire.com) - The 5th Brasil Investment Forum ("BIF 2022"), the largest foreign investment forum in Latin America jointly organized by Brazilian Trade and Investment Promotion Agency ("ApexBrasil"), Inter-American Development Bank and the Federal Government of Brazil, concluded successfully on 15 June 2022. During the forum, heavyweight speakers shared views on a range of topics, discussed the business environment and opportunities in Brazil, and promoted numbers of high-quality investments.BIF 2022 has achieved huge success with various record-breaking figures this year. The forum has attracted and presented 157 investment projects with an estimated investment value of USD66.4 billion, expecting to create 200,000 direct and indirect job opportunities in Brasil. The investment projects are mainly in transportation and infrastructure sectors, namely airports, railways, highways, ports, oil and gas, and energy. Among which, investors showed the strongest interest in railway market, 61 railway projects with a total investment value of US$31.81 billion were presented during the forum. The second most popular sector was road market. The contract value of the road projects reached USD 22.2 billion with the construction of 14,383 kilometers of roads. Moreover, 63 projects in airport sector worth UDS9.1 billion, 2 transmission auction projects in energy sector worth USD3.2 billion and 2 exploration projects in oil and gas sector worth USD246 million were presented during BIF 2022.Due to the Covid-19 pandemic, BIF 2022 adopted the online-offline hybrid format for the first time, however, the number of attendees this year exceeded 5,000, beating its historical records. 800 entrepreneurs and executives from 61 countries participated the forum at the World Trade Center of Sao Paulo, and over 4,000 potential investors from 100 countries participated online, totaling more than 5,000 attendees. The forum brought together over 350 representatives of the Brazilian federal and state governments as well as the CEOs of leading multinationals for 19 keynote speeches and discussions over the two consecutive days, covering a variety of hot topics including the latest business environment in Brazil, innovative business models, equity investment initiatives, and movements in global value chains. According to Augusto Pestana, president of ApexBrasil, the business environment in Brazil has been improving in an unprecedented magnitude, providing conditions for the entrepreneur to multiply his business, transforming the expansion into more goods and services, new products, and more jobs and income for millions of Brazilians. "Brazil is a country that modernizes itself and opens itself to the world with pragmatism and courage, a country that seeks the best standards and practices, as is well demonstrated by the beginning of our OECD entry process," said Pestana. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Ev Dynamics is Commissioned to Build Hong Kong’s First Accessible Electric Bus ACN Newswire

Ev Dynamics is Commissioned to Build Hong Kong’s First Accessible Electric Bus

HONG KONG, Jun 20, 2022 - (ACN Newswire via SEAPRWire.com) - Ev Dynamics (Holdings) Limited (the "Company", Stock Code: 476, together with its subsidiaries, collectively "Ev Dynamics" or the "Group"), a provider of new energy vehicles and integrated technology solutions, has received another purchase order from the Hong Kong Productivity Council to deliver a pure electric bus for use by a Hong Kong non-governmental organisation ("NGO"), which follows the Council's earlier order of electric buses for the Airport Authority Hong Kong and the Hong Kong Anti-Cancer Society.Ev Dynamics' pure electric bus is powered by sustainable high energy density batteries and is designed to adapt to and manoeuvre through complicated city road systems.The bus is equipped with an extra-low platform for easy accessibility for seniors and those with impaired mobility. It has enough space to house up to 33 regular seats and two wheelchairs.Developed by the Group under a new purchase agreement with the Hong Kong Productivity Council, the electric bus boasts a light aluminium alloy body structure with a highly efficient traction motor system, complemented by a full load-bearing electric bus chassis, high energy density batteries that ensure extended stable power output, and other innovative technological features. Moreover, the vehicle is set to be the first socially inclusive electric bus in Hong Kong, having been specifically designed to be accessible to seniors and those with disabilities, with features such as an extra-low platform for easy accessibility and enough space to house up to 33 regular seats and two wheelchairs. It also boasts the unique advantages of a relatively low weight and low energy consumption, making it a cost-efficient and sustainable transport solution. Subject to type approval, inspection and registration granted by the Transport Department, the Group expects delivery to be completed together with an EV charger installation project located next to the NGO's service centre in Tai Po by the end of next year, and will continue to provide quality after-sales maintenance and repair services to the end-user NGO.Miguel Valldecabres Polop, CEO of Ev Dynamics said, "We are always proud and excited when our products are brought to the public. In the past year, we have been expanding our global reach in the international electric vehicle market, especially in high-growth areas such as Europe, Latin America and Asia, but we are especially honoured to have received an order from our home market of Hong Kong. The pure electric bus showcases the Group's most innovative technological and product advantages, boasting zero emissions, reliable operation and sustainable design systems that will help to realise green targets related to the reduction of roadside air and noise pollution. The bus is also designed to be accessible to all members of society, including seniors and those with impaired mobility who may face obstacles when riding public transportation on a regular basis. We expect it to set the standard for energy efficient public transport, as the future of transport lies in electromobility, as well as further Ev Dynamics' market expansion in the local market." About Ev Dynamics (Holdings) Limited (Stock Code: 476)Ev Dynamics (Holdings) Limited is a pioneer and prominent player in China's new energy commercial vehicles market, as well as a whole-vehicle manufacturer of specialty passenger vehicles and new energy passenger vehicles. It is an integrated driving and logistics solutions provider with a solid technological foundation in diverse areas including new energy platform power systems and their key components. The Group has a production base in Chongqing, boasts extensive domestic and overseas sales networks, and focuses on serving high-growth markets in Southeast Asia, Europe and Latin America.Media EnquiriesStrategic Financial Relations LimitedVicky Lee +852 2864 4834 vicky.lee@sprg.com.hk Phoebe Leung +852 2114 4172 phoebe.leung@sprg.com.hkBrigid Lee +852 2114 4313 brigid.lee@sprg.com.hkWebsite: www.sprg.com.hk Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Mitsubishi Power Signs Decarbonization Agreement for Hydrogen Fuel Conversion with Leading Egyptian O&G Refinery ANRPC JCN Newswire

Mitsubishi Power Signs Decarbonization Agreement for Hydrogen Fuel Conversion with Leading Egyptian O&G Refinery ANRPC

Alexandria, Egypt /Duisburg, Germany, Jun 16, 2022 - (JCN Newswire via SEAPRWire.com) - Mitsubishi Power, a power brand of Mitsubishi Heavy Industries Ltd. (MHI) signed a full turnkey contract with leading Egyptian O&G Company Alexandria National Refining & Petrochemicals Company (ANRPC) to provide advanced hydrogen fuel conversion technology solutions, supporting the company to achieve its decarbonization goals. The solution will be installed at the ARNPC refinery plant in Alexandria, which provides 30% of Egypt's gasoline supply for domestic consumption.Under the terms of the contract, Mitsubishi Power will be responsible for the design, engineering, procurement, construction, and commissioning of fuel conversion solutions for the existing 100 ton/hour boiler, enabling it to fire up to 100% hydrogen by the end of 2023. This includes the installation of state-of-the-art hydrogen burner technology and advanced control solution to ensure efficient and safe operations.Commenting on the agreement, Salah Gaber, Chairman & CEO of ANRPC, said: "We are thrilled to partner with world technology leader Mitsubishi Power on innovative fuel conversion solutions that will help us to achieve our commercial goals while reducing our carbon footprint by 22,000 tons annually. Modernizing existing conventional boilers by enabling fuel conversion is a practical and important milestone to enable Egypt to deliver on its ambitious energy efficiency and decarbonization goals under the national Integrated Sustainable Energy Strategy. We look forward to working together with Mitsubishi Power to achieve all milestones and deliver the project on schedule."Falk Hoffmeister, Head of Service at Mitsubishi Power Europe GmbH, said: "We are proud to partner with Egypt's leading O&G refinery ANRPC, providing them with our groundbreaking hydrogen fuel conversion technology solutions, which will enable ANRPC to lower its CO2 emissions. The addition of hydrogen, considered to be the fuel of the future to ANRPC's fuel mix will deliver the flexibility they need to support them in achieving cost efficiencies. This latest contract is part of our continued commitment at Mitsubishi Power to develop technologies that convert existing thermal power systems to hydrogen and thus support our customers in the region to achieve their decarbonization goals."Khalid Salem, President, Middle East and North Africa at Mitsubishi Power said, "The ANRPC hydrogen fuel conversion project is a landmark project for Egypt's energy industry and we are honored to partner with O&G leader ANRPC to help them fulfill the country's ambition to become a low carbon energy leader. In the lead up to COP27, the ANRPC project is especially significant as it reflects Egypt's commitment to the development of a national hydrogen industry. At Mitsubishi Power, we will continue to work with our partners in Egypt and across the Middle East and North Africa to help them achieve decarbonization and deliver a sustainable future for the region."ANRPC, which was established in 1999, is the leading refining company in Egypt working under the umbrella of Egyptian general petroleum corporation (EGPC).Mitsubishi Power's hydrogen firing technology enables thermal power systems owners to decarbonize their existing plants with minimal modifications. This is part of Mitsubishi Power's mission to work with customers to create a sustainable roadmap to reduce CO₂ emissions.About Mitsubishi Power in Europe, Middle East and AfricaMitsubishi Power is a power solutions brand of Mitsubishi Heavy Industries, Ltd. (MHI), with a large presence across Europe, the Middle East and Africa. This includes centres of excellence in Germany, the United Kingdom, Saudi Arabia and the United Arab Emirates, besides vast customer support capabilities in many countries across the region. Mitsubishi Power designs, manufactures and maintains equipment and systems that drive decarbonization and ensures the delivery of reliable power. Among its solutions are a wide range of gas turbines, including hydrogen-fuelled gas turbines and solid-oxide fuel cells (SOFCs), and an experienced services business with an extensive reach across the entire region. Committed to providing exemplary service and working with customers, Mitsubishi Power's TOMONI intelligent solutions leverages advanced analytics, adaptive control technology, artificial intelligence and machine learning to make power plants smarter, lowering emissions, increasing flexibility and supporting decarbonization.For more information, please visit: https://power.mhi.com/regions/emea/PRESS CONTACT:Claudia WedemannMitsubishi Power Europe GmbHTel.: +49 203 8038 1368Email: c_wedemann@eumhi.com Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)
More